Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henry Grabowski

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
The American Journal of Managed Care|October 24, 2003
The ripple effects of a restrictive Medicaid formularyHenry Grabowski
Pharmacoeconomics|January 22, 2005
Are the economics of pharmaceutical research and development changing?: productivity, patents and political pressuresHenry Grabowski
Nature Reviews. Drug Discovery|May 13, 2008
Follow-on biologics: data exclusivity and the balance between innovation and competitionHenry Grabowski
Health Affairs (Project Hope)|May 12, 2005
Encouraging the development of new vaccinesHenry Grabowski
Journal of Medical Economics|February 29, 2024
Post-approval indications and clinical trials for cardiovascular drugs: some implications of the US Inflation Reduction ActHenry Grabowski, Genia Long
Health Affairs (Project Hope)|September 13, 2006
The market for follow-on biologics: how will it evolve?Henry Grabowski, Iain Cockburn, Genia Long
Nature Reviews. Drug Discovery|January 4, 2011
Data exclusivity for biologicsHenry Grabowski, Genia Long, Richard Mortimer
The New England Journal of Medicine|February 21, 2009
FDA review vouchersJeffrey Moe, Henry Grabowski, David Ridley
Seton Hall Law Review|July 12, 2011
Implementation of the biosimilar pathway: economic and policy issuesHenry Grabowski, Genia Long, Richard Mortimer
Nature Reviews. Drug Discovery|January 22, 2014
Biosimilar competition: lessons from EuropeHenry Grabowski, Rahul Guha, Maria Salgado
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
The American Journal of Managed Care|October 24, 2003
The ripple effects of a restrictive Medicaid formularyHenry Grabowski
Pharmacoeconomics|January 22, 2005
Are the economics of pharmaceutical research and development changing?: productivity, patents and political pressuresHenry Grabowski
Nature Reviews. Drug Discovery|May 13, 2008
Follow-on biologics: data exclusivity and the balance between innovation and competitionHenry Grabowski
Health Affairs (Project Hope)|May 12, 2005
Encouraging the development of new vaccinesHenry Grabowski
Journal of Medical Economics|February 29, 2024
Post-approval indications and clinical trials for cardiovascular drugs: some implications of the US Inflation Reduction ActHenry Grabowski, Genia Long
Health Affairs (Project Hope)|September 13, 2006
The market for follow-on biologics: how will it evolve?Henry Grabowski, Iain Cockburn, Genia Long
Nature Reviews. Drug Discovery|January 4, 2011
Data exclusivity for biologicsHenry Grabowski, Genia Long, Richard Mortimer
The New England Journal of Medicine|February 21, 2009
FDA review vouchersJeffrey Moe, Henry Grabowski, David Ridley
Seton Hall Law Review|July 12, 2011
Implementation of the biosimilar pathway: economic and policy issuesHenry Grabowski, Genia Long, Richard Mortimer
Nature Reviews. Drug Discovery|January 22, 2014
Biosimilar competition: lessons from EuropeHenry Grabowski, Rahul Guha, Maria Salgado
Pageof 2